Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of
macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and …

BACKGROUND Patients with coronavirus disease 2019 (COVID-19) develop pneumonia
generally associated with lymphopenia and a severe inflammatory response due to …

Abstract As the SARS-CoV-2 (COVID-19) pandemic spreads and the number of Bruton's
tyrosine kinase inhibitor (BTKi)-treated COVID-19-affected patients grows, we must consider …

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
| Blood | American Society of Hematology Skip to Main Content Advertisement Umbrella Alt …

Hyperinflammation is associated with increased mortality in coronavirus disease 2019
(COVID-19). In this retrospective, uncontrolled patient cohort with moderate-severe COVID …

Purpose Hyperinflammation in severe COVID-19 infection increases the risk of respiratory
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …

Abstract Objectives The Janus kinase (JAK) inhibitor baricitinib may block viral entry into
pneumocytes and prevent cytokine storm in patients with SARS-CoV-2 pneumonia. We …

Objective Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects,
we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using …

Baricitinib is an oral Janus kinase (JAK) 1/JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) …

Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no
placebo-controlled trials have focused specifically on severe/critical COVID, including …